- The trend backdrop is active with a 14-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
ANTHEM
NSI
Week ended 07 Aug 2026
Weekly Investor Report
ANTHEM BIOSCIENCES LTD · Healthcare · Biotechnology
Latest close
841.0 INR
3.8%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 16.2% above the Trend Line and sits at 89.0% of its 52-week range. The latest completed week returned 3.8%, after a 11.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 56/100.
Setup score
69
out of 100
Latest Close
841.0 INR
7 Aug 2026
1W Return
3.8%
latest completed week
4W Return
11.4%
short-term follow-through
12W Return
7.6%
quarterly tape
Trend Breadth
26.9%
14 of 52 weeks active
Volume Ratio
1.4x
vs 13-week average
- 1 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.8%
Latest completed week; four-week move 11.4%.
Indicator stack
60/57
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
56/100
29 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 16.2% above the Trend Line and sits at 89.0% of its 52-week range. The latest completed week returned 3.8%, after a 11.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.4x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7312-week average 0.73
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.73Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers
No recent accumulation markers. 1 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 11.4% over four weeks, 7.6% over 12 weeks, and 15.3% over one year. The current trend has remained active for 14 consecutive weeks.
Performance by holding period
Active trend streak14 weeks
Active weeks in one year14
Trend breadth26.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.55Latest activity-pressure read.
Pressure change-32.0%Four-week change in activity pressure.
Leadership16.13Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength37/100Blend of value, momentum, and quality. Underlying universe rank 64; rank 1 is best.
Value4/100Relative valuation strength. Underlying universe rank 97; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum74/100Medium-term price momentum. Underlying universe rank 27; rank 1 is best.
Growth77/100Revenue and earnings growth. Underlying universe rank 24; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework25/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 79.8x Price divided by trailing earnings.
- Price / sales
- 22.2x Market value relative to trailing revenue.
- EV / EBITDA
- 48.7x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 1.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 61.8% Gross profit retained from each unit of revenue.
- Operating margin
- 32.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 29.8% Free cash flow generated from revenue.
- Return on invested capital
- 18.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 15.2% Latest one-year revenue growth.
- EPS growth
- 31.1% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 6678.5% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.2% Cash dividends relative to market value.
- Buyback yield
- -0.1% Net share repurchases relative to market value.
- Shareholder yield
- 0.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment56/100
Weighted news tone is neutral across 29 relevant articles.
5 positive · 22 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-3.7%Distance below the 52-week high.
13-week volatility2.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+12.7%Week of 10 Apr.
Worst week-5.4%Week of 6 Mar.
Latest week+3.8%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains11
Flat weeks0
Modest losses10
Sharp losses1
Recent vol2.5%13-week weekly-return volatility.
Base vol4.3%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -2.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank13 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Biotechnology
4-week rank1 / 12
Group average-2.7%
Trend breadth83.3%
Trend83.3%active weekly trend signals
MD75.0%positive activity pressure
RS58.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape66/100
Trend, activity pressure, participation, and risk combine to a 66/100 tape read.
Indicator analysis72/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 4/12.
Activity pressure 0.73; 1 reversal markers Factors53/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 75 SVQF25/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1188.5 of 1580 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment56/100Weighted news tone is neutral across 29 relevant articles.
Anthem Biosciences shares gain 2.11%, trading at Rs 871.00 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 841.0 INR | 3.8% | 724.0 INR | 728.5 INR | 0.55 | 16.13 | 3.4M | On |
| 31 Jul 2026 | 810.0 INR | 5.2% | 717.0 INR | 726.4 INR | 0.47 | 13.03 | 2.4M | On |
| 24 Jul 2026 | 769.9 INR | -0.9% | 711.8 INR | 724.8 INR | 0.49 | 10.44 | 7.1M | On |
| 17 Jul 2026 | 777.0 INR | 3.0% | 707.9 INR | 723.9 INR | 0.58 | 9.00 | 5.1M | On |
| 10 Jul 2026 | 754.7 INR | -2.1% | 704.6 INR | 722.9 INR | 0.81 | - | 2.5M | On |
| 3 Jul 2026 | 770.9 INR | 1.2% | 702.8 INR | 722.3 INR | 1.03 | - | 324.1K | On |
| 26 Jun 2026 | 761.7 INR | -3.5% | 698.9 INR | 721.3 INR | 1.14 | - | 0 | On |
| 19 Jun 2026 | 789.0 INR | 0.3% | 694.7 INR | 720.4 INR | 1.32 | - | 1.3M | On |
| 12 Jun 2026 | 786.6 INR | 3.6% | 689.5 INR | 719.0 INR | 1.36 | - | 554.6K | On |
| 5 Jun 2026 | 759.5 INR | 0.2% | 686.0 INR | 717.5 INR | 1.45 | - | 264.8K | On |
| 29 May 2026 | 758.0 INR | -2.2% | 683.9 INR | 716.6 INR | 1.61 | - | 3.9M | On |
| 22 May 2026 | 775.1 INR | -0.8% | 682.3 INR | 715.6 INR | 1.59 | - | 3.5M | On |
| 15 May 2026 | 781.3 INR | -0.2% | 680.4 INR | 714.2 INR | 1.54 | - | 2.1M | On |
| 8 May 2026 | 782.6 INR | 3.2% | 679.6 INR | 712.6 INR | 1.35 | - | 1.2M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.